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pecia areata skin was extremely stimulating and raised the need for 
redefining Koch's postulates in the era of PCR. It also raises the 
question whether such putative etiologic or trigger factors are 
working with the susceptibility gene of the disease or with the 
severity gene of the immune response. 
There are significant needs in defining several aspects of basic 
hair biology including the hair cycle, and the control of potential 
molecules such as insulin growth factor 1 on hair growth. Mutant 
analysis of both the non-human and human mutants affecting hair 
structure should be extremely important as are studies of transgenic 
and knock-out mice. Dr. Chaplin, also a keynote speaker, made a 
strong case for defining all of the components of the HLA locus. He 
described 'a structural gene that does not have an obvious relationship 
to the immune system yet is extremely important for the hair follicle 
and the skin. The complexity of pathophysiology was emphasized with 
the example of a simple genetic disease as may be induced in the K6 
transgenic mice. Analysis and control and basic knowledge of the 
immune response will certainly help understand alopecia areata. 
SUMMARY 3S 
In addition to standardizing clinical criteria for clinical and 
molecular alopecia areata studies, it is strongly suggested that 
appropriate groups work with the Food and Drug Administration 
(FDA) to develop criteria for clinical trials in alopecia areata. In 
scleroderma, for example, criteria for clinical trials were developed 
by investigators in conjunction with the FDA. It is expected that 
systemic immune mediators will become available for trials and 
having such criteria will be extremely useful at that time. It was also 
suggested that investigators exchange sera whenever possible to 
enlarge the patient pool in genetic and immunologic studies and 
enhance the precision of interpreting the data. 
The National Alopecia Areata Foundation and National Institute 
of Arthritis and Musculoskeletal and Skin Diseases have been 
excellent catalysts for the development of research in alopecia 
areata. As we defme better the basic biology of the hair follicle, the 
immune response of the hair follicle, and genetic factors controlling 
the hair follicle, it is expected that these will lead to new preventive 
regimens as well as treatments for alopecia areata. 
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U
sing polymerase chain reaction (PCR) technique 
we have found evidence of cytomegalovirus 
(CMV) DNA in paraffin block sections of lesions 
of alopecia areata. 
Our interest in this association was first aroused 
by a 1s-year-old male patient who developed sore throat, arthral­
gias, fever, chills, and diffuse lymphadenopathy. Evaluation by 
several other physicians had failed to uncover an etiology. Tests for 
mononucleosis, among others, were negative. He developed wide­
spread alopecia areata with loss of most of the hair on his scalp and 
body. His symptoms suggested CMV infection; a convalescent 
serum IgG by EIA titer to CMV was 1.30 with positive being 
<0.25. Because of this one case we instituted further studies. 
Twenty-one of thirty-five alopecia areata patients had similarly 
elevated antibody titers. In situ hybridization tests on paraffin block 
biopsy specimens of 10 patients with alopecia areata were all 
negative. 
Specimens for PCR study were chosen from the archives of 
paraffin blocks at Baptist Memorial Hospital in Memphis, Tennes­
see. Specimen blocks were selected on the basis of characteristic 
morphology for alopecia areata, trichotillomania, or pattern hair 
loss. CMV antibody titer was not known for any of these specimens. 
DNA for PCR was obtained from paraffin-embedded sections by 
proteolytic digestion. CMV DNA sequences were amplified using 
two primer sets (directed against the CMV IE and LA regions) 
followed by hybridization with radiolabeled probes [1]. Appropri-
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ate positive and negative controls were included and consisted of 
DNA isolated from patients with CMV infection, plasmid DNA 
containing the IE gene region, samples lacking genomic DNA, and 
samples without primers. 
In addition, a primer set specific for human betaglobin (KM38-
GH20) was included to control for successful extraction of DNA 
from the paraffin. 
Twenty-one patient specimens were analyzed (1 0 alopecia 
areata; 11 from patients with other hair loss conditions [six 
androgenetic alopecia, five trichotillomania]). Of the alopecia 
areata samples, nine were positive for cytomegalovirus and one was 
negative; there were no DNA extraction failures. Of the other 
alopecias, all nine were negative for cytomegalovirus, with two 
DNA extraction failures. 
CMV, as a member of the herpes family of viruses, is thought to 
achieve latency following what is usually an inapparent clinical 
infection. The hair root is not an implausihle site for such latency to 
occur. Murine cytomegalovirus has been found in dermal papillae 
of hair follicles following subcutaneous injection of virus into CD1 
mice [2]. Coincidentally, these mice also developed marked alope­
cia or sparse hair growth in the inoculation sites. 
Alopecia areata has been considered likely to be a manifestation 
of auto-immunity [3], although it has been suggested, also, that its 
ubiquitous lymphocytic infiltrate may be serving a useful role [4]. 
A lymphocytic surveillance of not-quite-latent CMV would 
explain much of the behavior of alopecia areata with its tendency to 
intermittent remissions and relapses. We consider this the likeliest 
explanation of alopecia areata. 
Support for this possibility comes from the report by Grimes [5] 
of PCR evidence of CMV in 12 of 13 cases of vitiligo, a closely 
related condition. 
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T
he HLA antigen system, also known as the human 
major histocompatibility complex, is intimately in­
volved in immune responsiveness because these cell 
surface molecules present antigenic pep tides to the 
immune system for recognition of self and non-self, 
and also control the development of the T -lymphocyte repertoire 
[1]. As in other immune-mediated diseases [2], the HLA antigens 
associated with alopecia areata (AA) could influence the patient's 
ability to respond to immune challenge and may offer clues to the 
etiology, prognosis, and potential therapy of the disease. Multiple 
HLA class I and class II antigen associations have been described for 
alopecia areata (AA) [3-5]. No consensus has been attained for an 
HLA class I association, but studies of the associations ofHLA class 
II antigens with AA have indicated that the antigens HLA-DR4, 
DR5, and DQ3 are found with elevated frequency in AA patients 
compared with normal control frequencies in diverse populations. 
In this study, we have focused on patients with long-standing 
disease. Our objective was to determine which HLA class II 
antigens are associated with two forms of long-standing AA, i.e., 
long-standing patchy alopecia areata (AA) and long-standing alo­
pecia totalis/alopecia universalis (AT I AU), and to examine other 
factors, such as age of onset of disease and familial and patient 
histories of AA, for correlation with the two patient groups. 
MATERIALS AND METHODS 
The study included 131 patients divided into three groups: group I, patients 
newly diagnosed within the previous six months with any extent of alopecia 
areata (n = 31); group II, long-standing patchy alopecia areata (AA) of 
greater than 18 months' duration with greater than 25% hair loss but never 
AT/AU (n = 42); group III, long-standing AT or AU for more than 2 years 
at some point in their lives, with AT/AU defined as 100% scalp hair loss 
with or without body hair loss for 2 years or longer (n = 58). In group II, 
the duration of AA ranged from 18 months to 27 years with a mean of 8 
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years. In group III, the duration of AT/AU ranged from 2 to 54 years with 
a mean of 17 years. All patients were Caucasian and 18 years or older. 
Patients were typed for HLA class I and class II antigens by standard 
complement-dependent serologic methods and were typed for the 
subtypes of the HLA class II antigens by molecular methods, namely, 
sequence-specific priming (SSP) and sequence-specific oligonucleotide 
probing (SSOP). Statistical analysis was performed by chi-square analysis 
of two-by-two contingency tables. We applied a stringent correction 
factor to the p values obtained as is appropriate for analysis of HLA and 
disease data [2]. p values were corrected by the product of the number 
of antigens typed for times the number of comparisons made. DR and 
DQ p values were corrected for 15 DR-DQ antigens times two 
comparisons (for groups II and III), and DRB1 and DQBl allele p values 
were corrected for 63 possible DRB1 and DQB1 locus alleles times two 
comparisons = 1 26. 
As controls, we have utilized population data published in the proceed­
ings of the 11th International Histocompatibility Workshop, Yokohama, 
Japan [6] as controls for HLA class I and II antigen and gene freqnencies in 
North American Caucasians. 
Patient demographic data were gathered from all patients and included 
age of onset of the first patch of AA and family incidence of AA. 
RESULTS 
Table I shows a summary of the results of the serologic and 
molecular HLA typing of31 group 1,42 group II, and 58 group III 
patients. In addition, all 131 patients were combined into a single 
group referred to as "all patients." The frequency of DRll is 
significantly increased uniquely in group III patients, 43.1% com­
pared to control 18.5% (Pcor = 2.4 X 10-4). The frequency of the 
generic DQ antigen, DQ3, is significantly increased in both group 
II and group III patients and also in the group composed of all 
patients, 76.2% (Pcor = 0.03),86.2% (Pcor = 9 X 10-6), and 78.6% 
(Pcor = 6 X 10-7), respectively, compared with controls of 48.7%. 
Only in group I does DQ3 fail to achieve statistical significance 
when p values are corrected. 
Recent advances in typing of DNA for HLA antigens have vastly 
improved the accuracy of antigen identification and permitted the 
subtyping of the basic alleles many of which are undetectable by 
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